Mark D. Chin mark.chin.wg10@wharton.upenn.edu


University of California at San Diego, La Jolla, CA


B.S., Honors with Distinction, Management Science and Minor in Computer Science, 2004 University of Pennsylvania, School of Engineering and Applied Sciences, Philadelphia, PA


M.Sc., Biotechnology Candidate, 2010


An opportunity in corporate strategy, business development or venture capital in the life sciences industry.


Commercial Acceleration Program, Philadelphia, PA Practice Leader, 2008-2010 Lead a team of Wharton/UPenn students to conduct projects for BioAdvance, Quaker BioVenture’s Greenhouse Fund, and UPenn’s Center for Technology Transfer. Evaluate the market opportunity for medical tech- nologies based on size of addressable market, competitive dynamics, and novelty of technology.


Genentech, South San Francisco, CA BioOncology Pipeline Market Planning Intern, Summer 2009


Delivered recommendations that addressed unmet patient needs and strategic product considerations in anticipation of a pipeline product launch. Estimated the value of a subset of patients by building a detailed forecast model.


Professional Service Solutions, Emeryville, CA Manager 2006-2008; Senior Associate 2005-2006


Responsible for the managing health- care strategy consulting projects by leading a team through proposal creation, development/execution of the project approach, and delivery of client recommendations. Projects included developing corporate strate- gies and commercialization plans, identifying acquisition, licensing and co-promote targets and conducting due diligence.


Patpatia & Associates, Berkeley, CA Senior Business Analyst, 2004-2005 Led significant parts of financial services strategy consulting projects.


An opportunity in strategy or commercial operations within the healthcare industry.


Celgene, Summit, NJ


Corporate Strategy Summer Associate, Summer 2009


Built comprehensive 10-year strategic plan by validating and incorporating inputs from global, cross-functional stakeholders. Analyzed impact of options, including clinical develop- ment and commercialization partner- ships, to identify operating expense optimization opportunities. Supported development of consolidated P&Ls for Immunology & Inflammation and Solid Tumor franchises.


A.T. Kearney, New York, NY and Paris, France Associate 2007-2008; Sr. Business Analyst 2006; Business Analyst 2004-2005 Worked primarily with global pharma- ceutical and consumer healthcare clients to address strategic questions in M&A integration, portfolio man- agement, product commercialization, and manufacturing operations. Selected experience includes: Modeled future-state market scenarios for mature antihypertensive product port- folio to create life cycle management strategy. Conducted market research to craft commercialization plan for central nervous system drug. Optimized consumer healthcare product portfolio, incorporating market requirements and operations cost drivers. Led initial phase of global manufacturing inte- gration in EMEA by coordinating 10- person cross-functional client team. Facilitated link between Bracket Pricing team and Terms of Sale team to consolidate policy recommendations and to develop customer communication documents and plan.


An investment or development opportunity in health care real estate.


UBS Investment Bank, Los Angeles, CA Summer Associate, Summer 2009 Conducted debt refinancing analyses for a large-cap software company with $0.5B in “in-the-money” convertible notes. Created financial statement and cash flow forecasts to evaluate various refinancing options including new convertible notes as well as high-yield debt. Other projects included the preparation of a year-end performance analysis of UBS’ Technology Investment Banking group.


Houlihan Lokey Howard & Zukin, San Francisco, CA


Senior Financial Analyst, 2005-2008 Conducted corporate valuations, fairness opinions, and purchase price allocations for companies ranging in size from $50M to $10B in annual revenue. Used quantitative and quali- tative analyses including discounted cash flow analyses, comparable- company and comparable transaction analyses, cash flow modeling, capital structure waterfall analyses and industry research.


B. Riley & Co., Los Angeles, CA Equity Research Associate, 2003-2005 Conducted value-focused, equity research and valuation of small- and mid-cap technology companies. Tasks included building financial models, interviewing and maintaining rela- tionships with the senior management of monitored companies and prepar- ing research reports for institutional investors.


Kelsey L. Christian


kelsey.christian.wg10@wharton.upenn.edu University of Pennsylvania, Philadelphia, PA B.S.E., Cum Laude, Bioengineering, 2004


Michael L. Cogan michael.cogan.wg10@wharton.upenn.edu


University of California Los Angeles (UCLA) Los Angeles, CA


B.S., Mathematics / Economics, 2003


9


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40